Amarin

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

Retrieved on: 
Thursday, October 26, 2023
CH.B, MB, Plasma, Health, DHA, SVP, History, Eicosapentaenoic acid, American Heart Association, Amarin, Diabetes, Research, Metabolic syndrome, EPA, Abadir Umar ar-Rida, Risk, IPE, Abstract, Professional corporation, AHA, Molina Healthcare, Patient, Cardiovascular disease, Pharmaceutical industry, Dietary supplement

This subgroup was almost exclusively comprised of patients with established cardiovascular disease.

Key Points: 
  • This subgroup was almost exclusively comprised of patients with established cardiovascular disease.
  • Lastly, an abstract describing the demographic/clinical characteristics of US patients taking icosapent ethyl, focusing on those with diabetes, will also be presented.
  • These and other new findings will be presented by a variety of international academic collaborators based on research or analyses supported by Amarin.
  • Featured Amarin-supported abstracts to be presented at AHA Scientific Sessions 2023 include:
    Michael Miller, Deepak L. Bhatt, Eliot A. Brinton, Terry A Jacobson et al...

 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

Retrieved on: 
Thursday, October 19, 2023
Q&A, Professional corporation, Amarin, ET, Conference, Management

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss the Company’s third quarter 2023 financial results on Wednesday, November 1st, 2023 at 8:00 a.m.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss the Company’s third quarter 2023 financial results on Wednesday, November 1st, 2023 at 8:00 a.m.
  • Starting on October 19th at 8:00 am ET, all shareholders can submit questions by visiting: https://app.saytechnologies.com/amarin-2023-q3 .
  • The conference call with management will follow the release of the Company’s third quarter 2023 financial results in the pre-market hours.
  • Conference Call and Webcast Information:
    Access to the live call:
    Dial in within the United States: 877-545-0523

Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy

Retrieved on: 
Wednesday, August 9, 2023
Cardiovascular disease, CVD, Professional corporation, Death, CTS, Patient, Physician, Risk, CPR, Disease, Health insurance, Pharmaceutical industry, Health, Amarin

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced pricing and reimbursement updates for VAZKEPA (icosapent ethyl) in the Netherlands and Italy.

Key Points: 
  • – Italy’s AIFA Pricing & Reimbursement Committee (CPR) Issues Negative Decision on VAZKEPA; Follows Positive Scientific Assessment by the Italian Scientific Technical Committee (CTS) –
    DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced pricing and reimbursement updates for VAZKEPA (icosapent ethyl) in the Netherlands and Italy.
  • The national reimbursement will now allow Amarin to begin efforts to commercialize VAZKEPA across the Netherlands in September.
  • Cardiovascular disease (CVD) is a substantial issue in the Netherlands with ~1.7 million people suffering from the disease.
  • Amarin is continuing to engage with AIFA on all possible options – including a resubmission - to secure a positive pricing outcome and ensure access to VAZKEPA in the interest of patients across Italy.

Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

Retrieved on: 
Tuesday, August 8, 2023
Male, Research and development, National Defense Authorization Act, Diabetes, Marketing, MOH, Cardiovascular disease, Woman, Medicine, Medication, Professional corporation, Ministry, Development, Death, Capsule, Patient, Risk, Pedigree, Eicosapentaenoic acid, Ageing, Cardiology, Regulation, Female, Pharmaceutical industry, Health, Amarin

DUBLIN, Ireland, BRIDGEWATER, N.J and PETAH TIKVA, ISRAEL, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and Neopharm Israel announced today that the two companies have entered into an exclusive marketing and commercialization agreement for VAZKEPA® (icosapent ethyl) in the State of Israel, Gaza, West Bank and the territories of the Palestinian Authority. VAZKEPA capsules are the first prescription treatment comprised solely of the active ingredient, icosapent ethyl, a highly purified form of eicosapentaenoic acid.

Key Points: 
  • VAZKEPA capsules are the first prescription treatment comprised solely of the active ingredient, icosapent ethyl, a highly purified form of eicosapentaenoic acid.
  • "We are excited to announce this agreement with Neopharm, a leading provider of pharmaceutical commercialization in Israel,” said Patrick Holt, President & CEO, Amarin.
  • “Neopharm is well-positioned with its commercial capabilities, as well as its pedigree and experience in cardiology and related disease categories, to enable access to this important medicine for patients in Israel."
  • Amarin will be responsible for supplying finished product to Neopharm at a transfer price paid to Amarin.

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

Retrieved on: 
Monday, August 7, 2023
Knowledge, Heart, National Health Service, Myocardial infarction, MI, Hospital, Moyamoya disease, Acute coronary syndrome, Stroke, Cardiovascular disease, Splenic infarction, British Heart Foundation, Risk assessment, CVD, Glasgow Royal Infirmary, History, Healthcare Improvement Scotland, Professional corporation, Death, SMC, Molina Healthcare, Patient, ACS, Risk, LDL, Eicosapentaenoic acid, NHS, NICE, National Institute for Health and Care Excellence, Pharmaceutical industry, Nursing, Amarin, NHS Scotland

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announces that the Scottish Medicines Consortium (SMC) has accepted VAZKEPA® (icosapent ethyl) for reimbursement with a Patient Access Scheme* for secondary prevention in patients treated with a stable dose of statins, low-density lipoprotein (LDL) cholesterol levels >1.04mmol/L and ≤2.60mmol/L, raised fasting triglycerides (≥1.7mmol/L) and with established cardiovascular disease (CVD) defined as a history of any of the following: acute coronary syndrome (ACS) such as myocardial infarction (MI) or unstable angina needing hospitalization; coronary or other arterial revascularization procedures; coronary heart disease; ischaemic stroke; or peripheral arterial disease.1

Key Points: 
  • This represents an important step forward in the fight against CVD in Scotland,” said Professor Adrian Brady, Consultant Cardiologist at Glasgow Royal Infirmary.
  • Amarin is working with Health Boards across Scotland to secure formulary inclusion and ensure that as many patients as possible among the eligible population will have access to VAZKEPA® by the end of 2023.
  • * Patient Access Schemes are confidential pricing agreements proposed by pharmaceutical companies to enable patient access to new medicines and treatments.
  • The Patient Access Scheme Assessment Group (PASAG) reviews and advises NHSScotland on the feasibility of proposed schemes for implementation.

Amarin Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 2, 2023
Acceleration, England and Wales, Pressure, Partnership, Prescription, HTA, GAAP, England, Forecasting, Professional corporation, IPE, Medicare, Gold, Patient, Investment, Risk, Organization, Commercial, Kingdom, Research, Health technology assessment, Total, Pharmaceutical industry, Rare-earth element, Renewable energy, Cryptocurrency, Bank, Amarin

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced financial results for the quarter ended June 30, 2023 and provided an update on company operations.

Key Points: 
  • -- Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License and Royalty Revenues, of Which $11 Million is Non-Cash --
    DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced financial results for the quarter ended June 30, 2023 and provided an update on company operations.
  • Mr. Holt continued, “Amarin’s second quarter performance was marked by continued revenue generation in the U.S. and a cash positive quarter.
  • U.S. product net revenue was $64.6 million in the second quarter of 2023, a decline of $17.7 million versus the first quarter of 2023, a decrease of 22% sequentially.
  • In the second quarter of 2023, Amarin secured regulatory approval for VASCEPA in China and the Kingdom of Saudi Arabia.

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

Retrieved on: 
Monday, July 31, 2023
Partnership, CVD, Amarin, Professional corporation, Hyperlipidemia, EPA, Capsule, Patient, Disease, Eicosapentaenoic acid, Mortality, Pharmaceutical industry, ASEAN, Lotus

"We are excited to announce this exclusive partnership with Lotus, a leading pharmaceutical commercialization partner in Asia,” said Patrick Holt, President & CEO, Amarin. “Lotus’ strong commercialization capabilities and footprint across ASEAN markets and South Korea make them the ideal partner to help us expand patient access to VAZKEPA -- an innovative treatment option to reduce cardiovascular risk -- across the region and fuel our international growth.”

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J. and NANTOU, Taiwan, July 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and Lotus Pharmaceuticals (1795:TT; “Lotus”) today announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize VAZKEPA® (icosapent ethyl) across 10 countries, including nine in Southeast Asia (the Association of Southeast Asian Nations - ASEAN) and South Korea.
  • "We are excited to announce this exclusive partnership with Lotus, a leading pharmaceutical commercialization partner in Asia,” said Patrick Holt, President & CEO, Amarin.
  • As part of the agreement, Amarin will receive an upfront payment as well as pricing and reimbursement and sales milestone payments based on net sales of the product.
  • Amarin will be responsible for supplying finished product to Lotus at a pre-defined supply price.

Lexicon Elects Diane E. Sullivan to Board of Directors

Retrieved on: 
Friday, July 28, 2023
GSK plc, Marketing, AstraZeneca, Sequah Medicine Company, Acquisition, Novartis, Avanos Medical, Wyeth, Lexicon, Pharmaceutical industry, Amarin, Pfizer

THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its Board of Directors.

Key Points: 
  • THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its Board of Directors.
  • Ms. Sullivan brings extensive commercialization, strategy, and market access experience to the Lexicon Board of Directors.
  • “We are grateful to Frank for his service on the Board of Directors and appreciate his contributions to the company’s progress,” said Ray Debbane, Lexicon’s Board Chair.
  • We are very excited to have Diane join the Board of Directors.”

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

Retrieved on: 
Wednesday, July 26, 2023
Abstract, Risk, ESC Congress, MB, European Society of Cardiology, EST, Research, Biomarker, CH.B, MACE, Amarin, Professional corporation, IPE, Congress, EPA, Ethyl eicosapentaenoic acid, Patient, Eicosapentaenoic acid, ESC, SVP, MPH, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023.
  • This new research includes, along with other topics, the review of the contribution of eicosapentaenoic acid (EPA) and other biomarkers to MACE reduction by icosapent ethyl (IPE).
  • Featured Amarin-supported abstracts to be presented at ESC Congress 2023 include:
    -Available: August 26 at 9:24 CET (3:24 a.m. EST) in Lisbon Room
    Session: What's new in lipid lowering?
  • CH.B., SVP, Chief Medical Officer and Head of Global Medical Affairs, Amarin.

Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain

Retrieved on: 
Tuesday, July 25, 2023
Stroke, Workplace, INE, Cardiovascular disease, Splenic infarction, Peaceful transition of power, CVD, Amarin, Professional corporation, Committee, GDP, Patient, Risk, Instituto Nacional de Estadística (Spain), Growth, Death, Disease, Health insurance, Pharmaceutical industry, Health

DUBLIN, Ireland and BRIDGEWATER, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announces that following the most recent meeting of the Spanish Drug Pricing Committee (Comisión Interministerial de Precios de los Medicamentos) on July 24, 2023, the Committee is recommending the national reimbursement of VAZKEPA® (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in patients with high cardiovascular risk1.

Key Points: 
  • “Cardiovascular disease is still one of Spain’s leading causes of death and patients with this disease need access to new treatments that can reduce their risk of having another event.
  • According to data published by the Spanish National Statistics Institute (INE), in 2020 around 200,000 people died as a result of cardiovascular disease (CVD), making it the leading cause of death for the Spanish population as a whole, ahead of cancer2.
  • In addition, more than 457,000 new cases are diagnosed each year in Spain.
  • “Our team in Spain will now be laser-focused on supporting efforts to reach healthcare professionals and drive awareness and adoption of this important new treatment for patients.